Compare ALNY & RKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALNY | RKT |
|---|---|---|
| Founded | 2002 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9B | 54.1B |
| IPO Year | 2004 | 2020 |
| Metric | ALNY | RKT |
|---|---|---|
| Price | $394.40 | $21.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 14 |
| Target Price | ★ $479.45 | $19.46 |
| AVG Volume (30 Days) | 1.6M | ★ 17.5M |
| Earning Date | 02-12-2026 | 10-30-2025 |
| Dividend Yield | N/A | ★ 4.02% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | $3,210,070,000.00 | ★ $6,098,944,000.00 |
| Revenue This Year | $70.04 | $15.19 |
| Revenue Next Year | $43.08 | $71.65 |
| P/E Ratio | $1,213.17 | ★ N/A |
| Revenue Growth | ★ 53.24 | 41.68 |
| 52 Week Low | $205.87 | $10.06 |
| 52 Week High | $495.55 | $22.56 |
| Indicator | ALNY | RKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 67.68 |
| Support Level | $393.64 | $19.17 |
| Resistance Level | $407.22 | $20.27 |
| Average True Range (ATR) | 9.87 | 0.68 |
| MACD | 0.91 | 0.13 |
| Stochastic Oscillator | 36.05 | 91.69 |
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.